X Zhang1, L Yang, Z Qiao. 1. The Institute of Hematology, Shanxi Medical University, Taiyuan, 030001.
Abstract
OBJECTIVE: To compare the therapeutic effects and reactions of intra venous arsenic trioxide and all-trans retinoic acid in treating patients with acute promyelocytic leukemia (APL). METHODS:75 cases of APL were randomized either to arsenic trioxide (37) or to all-trans retinoic acid (38). The rates of complete remission (CR), disease free survival (DFS) and side effects were observed. RESULTS: In the two groups of patients with APL, the rate of CR was 86.4% and 84.2%. There was also no significant difference in the rate of DSF phase of CR (P > 0.05). The side effects of these two medications in therapeutic dose were mild and there was no cross resistance between them. CONCLUSION:Arsenic trioxide can lead to apoptosis of leukemic cells and might be a new promising drug to induce differentiation.
RCT Entities:
OBJECTIVE: To compare the therapeutic effects and reactions of intra venous arsenic trioxide and all-transretinoic acid in treating patients with acute promyelocytic leukemia (APL). METHODS: 75 cases of APL were randomized either to arsenic trioxide (37) or to all-transretinoic acid (38). The rates of complete remission (CR), disease free survival (DFS) and side effects were observed. RESULTS: In the two groups of patients with APL, the rate of CR was 86.4% and 84.2%. There was also no significant difference in the rate of DSF phase of CR (P > 0.05). The side effects of these two medications in therapeutic dose were mild and there was no cross resistance between them. CONCLUSION:Arsenic trioxide can lead to apoptosis of leukemic cells and might be a new promising drug to induce differentiation.